Adapting Immunotherapy and Gene Editing Based Strategies for Targeting HIV Reservoirs in the CNS: Potential Benefits and Risks (R01, R21 Clinical Trial Optional)

Funding Agency:
National Institutes of Health


This Funding Opportunity Announcement (FOA) invites research grant applications that propose studies for adapting immunotherapy and gene therapy-based strategies to target viral reservoirs in the central nervous system (CNS) and examine the potential risks of applying such technologies to the brain. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborations are encouraged but not required. High risk/high payoff projects that lack preliminary data may be most appropriate for the companion R21 FOA, RFA-MH-21-226, while applicants with preliminary data may wish to apply using the R01 mechanism.


  • Letter of Intent Due Date(s): July 27, 2021

  • AIDS Application: August 27, 2021

RFA-MH-21-225 Expiration Date August 28, 2021




Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

August 27, 2021